UAE’s Mubadala Healthcare contributes to UK COVID-19 diabetes drug trial
- Date: 10-Nov-2020
- Source: Arab News
- Sector:Healthcare
- Country:uae-top-picks
UAE’s Mubadala Healthcare contributes to UK COVID-19 diabetes drug trial
The Arcadia trial began on Sept. 29 and involved hospitalized patients with mild to moderate COVID-19 symptoms. (File/Reuters)
Short Url
UAE's Mubadala Healthcare contributes to UK COVID-19 diabetes drug trial
The trial, known as Arcadia, was approved following preclinical research
If successful, it could be prescribed by doctors for people with diabetes
Updated 09 November 2020
Follow @arabnews
DUBAI: A leading UAE health care provider revealed that it was contributing to a British-based drug trial that will help patients with diabetes overcome the effects of the coronavirus disease (COVID-19).
Mubadala Healthcare is part-funding the trial of an immune-dampening drug approved by the UK's Medicines and Healthcare products Regulatory Agency.
The trial, known